Decitabine
Essential Thrombocythemia
University of WashingtonSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Essential Thrombocythemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS Thomas Jefferson University | Phase 2 | BB |
Fludarabine Thomas Jefferson University | Phase 2 | BB |
Ruxolitinib University of Washington | Phase 2 | B |
Cyclophosphamide Thomas Jefferson University | Phase 2 | B |
Hycamtin National Cancer Institute (NCI) | Phase 2 | B |
View all 31 →
Same molecule, other indications
Decitabine is also rated in:
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →